European Journal of Cancer
Volume 45, Issue 1 , Pages 74-81 , January 2009

Harmonisation of multi-centre real-time reverse-transcribed PCR results of a candidate prognostic marker in breast cancer: An EU-FP6 supported study of members of the EORTC – PathoBiology Group

  • P.N. Span

      Affiliations

    • Department of Chemical Endocrinology 479, Radboud University Nijmegen Medical Centre, P.O. Box 9101, NL-6500 HB Nijmegen, Nijmegen, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 24 3614279; fax: +31 24 3541484.
    • ,
  • A.M. Sieuwerts

      Affiliations

    • Department of Medical Oncology, Josephine Nefkens Institute, Erasmus MC, Rotterdam, The Netherlands
    • ,
  • J.J.T.M. Heuvel

      Affiliations

    • Department of Chemical Endocrinology 479, Radboud University Nijmegen Medical Centre, P.O. Box 9101, NL-6500 HB Nijmegen, Nijmegen, The Netherlands
    • ,
  • F. Spyratos

      Affiliations

    • Centre René Huguenin, Laboratoire d’Oncogénetique/INSERMU735, St-Cloud, France
    • ,
  • M.J. Duffy

      Affiliations

    • Department of Pathology and Laboratory Medicine, St. Vincent’s University Hospital, Dublin, Ireland
    • UCD School of Medicine and Medical Science, Conway Institute, University College, Dublin, Ireland
    • ,
  • S. Eppenberger-Castori

      Affiliations

    • Stiftung Tumorbank Basel, Riehen, Switzerland
    • ,
  • S. Vacher

      Affiliations

    • Centre René Huguenin, Laboratoire d’Oncogénetique/INSERMU735, St-Cloud, France
    • ,
  • K. O’Brien

      Affiliations

    • Department of Pathology and Laboratory Medicine, St. Vincent’s University Hospital, Dublin, Ireland
    • UCD School of Medicine and Medical Science, Conway Institute, University College, Dublin, Ireland
    • ,
  • E. McKiernan

      Affiliations

    • Department of Pathology and Laboratory Medicine, St. Vincent’s University Hospital, Dublin, Ireland
    • UCD School of Medicine and Medical Science, Conway Institute, University College, Dublin, Ireland
    • ,
  • A. Pierce

      Affiliations

    • Department of Pathology and Laboratory Medicine, St. Vincent’s University Hospital, Dublin, Ireland
    • UCD School of Medicine and Medical Science, Conway Institute, University College, Dublin, Ireland
    • ,
  • V. Vuaroqueaux

      Affiliations

    • Stiftung Tumorbank Basel, Riehen, Switzerland
    • ,
  • J.A. Foekens

      Affiliations

    • Department of Medical Oncology, Josephine Nefkens Institute, Erasmus MC, Rotterdam, The Netherlands
    • ,
  • F.C.G.J. Sweep

      Affiliations

    • Department of Chemical Endocrinology 479, Radboud University Nijmegen Medical Centre, P.O. Box 9101, NL-6500 HB Nijmegen, Nijmegen, The Netherlands
    • ,
  • J.W.M. Martens

      Affiliations

    • Department of Medical Oncology, Josephine Nefkens Institute, Erasmus MC, Rotterdam, The Netherlands

Received 9 July 2008 ,Revised 11 September 2008 ,Accepted 30 September 2008.

References 

  1. Elledge RM, Green S, Pugh R, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immunohistochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer. 2000;89:111–117
  2. Geurts-Moespot J, Leake R, Benraad TJ, Sweep CG. Twenty years of experience with the steroid receptor external quality assessment program – the paradigm for tumour biomarker EQA studies. On behalf of the EORTC Receptor and Biomarker Study Group. Int J Oncol. 2000;17:13–22
  3. Sweep CG, Geurts-Moespot J. EORTC external quality assurance program for ER and PgR measurements: trial 1998/1999. European Organisation for Research and Treatment of Cancer. Int J Biol Markers. 2000;15:62–69
  4. Sweep CG, Geurts-Moespot J, Grebenschikov N, et al. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br J Cancer. 1998;78:1434–1441
  5. McGuire W. Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst. 1991;83:154–155
  6. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 1996;88:1456–1466
  7. Hayes DF, Trock B, Harris AL. Assessing the clinical impact of prognostic factors: when is “statistically significant” clinically useful?. Breast Cancer Res Treat. 1998;52:305–319
  8. Janicke F, Prechtl A, Thomssen C, et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst. 2001;93:913–920
  9. Look MP, van Putten WL, Duffy MJ, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst. 2002;94:116–128
  10. Maier S, Nimmrich I, Koenig T, et al. DNA-methylation status of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients – technical and clinical validation in a multicenter setting in collaboration with the EORTC PathoBiology Group. Eur J Cancer. 2007;43:1679–1686
  11. Nimmrich I, Sieuwerts AM, Meijer-van Gelder ME, et al. DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients. Breast Cancer Res Treat. 2008;111:429–437
  12. Kioussi C, Briata P, Baek SH, et al. Identification of a Wnt/Dvl/beta-Catenin→Pitx2 pathway mediating cell-type-specific proliferation during development. Cell. 2002;111:673–685
  13. Quentien MH, Barlier A, Franc JL, Pellegrini I, Brue T, Enjalbert A. Pituitary transcription factors: from congenital deficiencies to gene therapy. J Neuroendocrinol. 2006;18:633–642
  14. Kitamura K, Miura H, Miyagawa-Tomita S, et al. Mouse Pitx2 deficiency leads to anomalies of the ventral body wall, heart, extra- and periocular mesoderm and right pulmonary isomerism. Development. 1999;126:5749–5758
  15. de Kok JB, Roelofs RW, Giesendorf BA, et al. Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest. 2005;85:154–159
  16. Marubini E, Verderio P, Casini Raggi C, Pazzagli M, Orlando C. Statistical diagnostics emerging from external quality control of real-time PCR. Int J Biol Markers. 2004;19:141–146
  17. Raggi CC, Verderio P, Pazzagli M, et al. An Italian program of external quality control for quantitative assays based on real-time PCR with Taq-ManTM probes. Clin Chem Lab Med. 2005;43:542–548
  18. Ramsden SC, Daly S, Geilenkeuser WJ, et al. EQUAL-quant: an international external quality assessment scheme for real-time PCR. Clin Chem. 2006;52:1584–1591
  19. Span PN, Waanders E, Manders P, et al. Mammaglobin is associated with low-grade, steroid receptor-positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival time. J Clin Oncol. 2004;22:691–698
  20. Jansen MP, Sieuwerts AM, Look MP, et al. HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study. J Clin Oncol. 2007;25:662–668
  21. Helleman J, Jansen MP, Ruigrok-Ritstier K, et al. Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin Cancer Res. 2008;14:5555–5564

PII: S0959-8049(08)00790-9

doi: 10.1016/j.ejca.2008.09.030

European Journal of Cancer
Volume 45, Issue 1 , Pages 74-81 , January 2009

Article Tools

* Image Usage & Resolution